00014024792022Q3FALSE--12-3133.332.08.6667.3333.333300014024792022-01-012022-09-3000014024792022-11-08xbrli:shares00014024792022-09-30iso4217:USD00014024792021-12-31iso4217:USDxbrli:shares0001402479medavail:PharmacyAndHardwareMember2022-07-012022-09-300001402479medavail:PharmacyAndHardwareMember2021-07-012021-09-300001402479medavail:PharmacyAndHardwareMember2022-01-012022-09-300001402479medavail:PharmacyAndHardwareMember2021-01-012021-09-300001402479us-gaap:ServiceMember2022-07-012022-09-300001402479us-gaap:ServiceMember2021-07-012021-09-300001402479us-gaap:ServiceMember2022-01-012022-09-300001402479us-gaap:ServiceMember2021-01-012021-09-3000014024792022-07-012022-09-3000014024792021-07-012021-09-3000014024792021-01-012021-09-300001402479us-gaap:CommonStockMember2022-06-300001402479us-gaap:PreferredStockMember2022-06-300001402479us-gaap:WarrantMember2022-06-300001402479us-gaap:AdditionalPaidInCapitalMember2022-06-300001402479us-gaap:RetainedEarningsMember2022-06-300001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000014024792022-06-300001402479us-gaap:RetainedEarningsMember2022-07-012022-09-300001402479us-gaap:CommonStockMember2022-07-012022-09-300001402479us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001402479us-gaap:WarrantMember2022-07-012022-09-300001402479us-gaap:CommonStockMember2022-09-300001402479us-gaap:PreferredStockMember2022-09-300001402479us-gaap:WarrantMember2022-09-300001402479us-gaap:AdditionalPaidInCapitalMember2022-09-300001402479us-gaap:RetainedEarningsMember2022-09-300001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001402479us-gaap:CommonStockMember2021-12-310001402479us-gaap:PreferredStockMember2021-12-310001402479us-gaap:WarrantMember2021-12-310001402479us-gaap:AdditionalPaidInCapitalMember2021-12-310001402479us-gaap:RetainedEarningsMember2021-12-310001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001402479us-gaap:RetainedEarningsMember2022-01-012022-09-300001402479us-gaap:CommonStockMember2022-01-012022-09-300001402479us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001402479us-gaap:WarrantMember2022-01-012022-09-300001402479us-gaap:CommonStockMember2021-06-300001402479us-gaap:PreferredStockMember2021-06-300001402479us-gaap:WarrantMember2021-06-300001402479us-gaap:AdditionalPaidInCapitalMember2021-06-300001402479us-gaap:RetainedEarningsMember2021-06-300001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000014024792021-06-300001402479us-gaap:RetainedEarningsMember2021-07-012021-09-300001402479us-gaap:CommonStockMember2021-07-012021-09-300001402479us-gaap:WarrantMember2021-07-012021-09-300001402479us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001402479us-gaap:CommonStockMember2021-09-300001402479us-gaap:PreferredStockMember2021-09-300001402479us-gaap:WarrantMember2021-09-300001402479us-gaap:AdditionalPaidInCapitalMember2021-09-300001402479us-gaap:RetainedEarningsMember2021-09-300001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000014024792021-09-300001402479us-gaap:CommonStockMember2020-12-310001402479us-gaap:PreferredStockMember2020-12-310001402479us-gaap:WarrantMember2020-12-310001402479us-gaap:AdditionalPaidInCapitalMember2020-12-310001402479us-gaap:RetainedEarningsMember2020-12-310001402479us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100014024792020-12-310001402479us-gaap:RetainedEarningsMember2021-01-012021-09-300001402479us-gaap:CommonStockMember2021-01-012021-09-300001402479us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001402479us-gaap:WarrantMember2021-01-012021-09-300001402479us-gaap:PrivatePlacementMember2022-04-012022-04-300001402479us-gaap:PrivatePlacementMember2022-07-012022-07-0100014024792022-07-010001402479srt:MinimumMember2022-04-012022-04-300001402479srt:MaximumMember2022-04-012022-04-300001402479us-gaap:SecuredDebtMembermedavail:SVBTermLoanMember2021-01-012021-12-310001402479us-gaap:PrivatePlacementMember2022-07-012022-07-310001402479srt:ScenarioPreviouslyReportedMember2021-07-012021-09-300001402479srt:RestatementAdjustmentMember2021-07-012021-09-300001402479srt:ScenarioPreviouslyReportedMember2021-01-012021-09-300001402479srt:RestatementAdjustmentMember2021-01-012021-09-300001402479medavail:WarrantsIssuedMay92018Member2022-01-012022-09-300001402479medavail:WarrantsIssuedFebruary112020Member2022-01-012022-09-300001402479medavail:WarrantsIssuedJune292020Member2022-01-012022-09-300001402479medavail:WarrantsIssuedNovember182020Member2022-01-012022-09-300001402479medavail:WarrantsIssuedNovember182020OutstandingMember2022-01-012022-09-300001402479us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001402479us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001402479us-gaap:WarrantMember2022-01-012022-09-300001402479us-gaap:WarrantMember2021-01-012021-12-310001402479us-gaap:FairValueMeasurementsRecurringMember2022-09-300001402479us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001402479us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300001402479us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001402479us-gaap:FairValueMeasurementsRecurringMember2021-12-310001402479us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001402479us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001402479us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001402479medavail:GuaranteeForPurchasingCardsMember2022-01-012022-09-300001402479medavail:LetterOfCreditSecurityMember2022-09-3000014024792022-02-280001402479medavail:PharmacyMember2022-07-012022-09-300001402479medavail:PharmacyMember2021-07-012021-09-300001402479medavail:PharmacyMember2022-01-012022-09-300001402479medavail:PharmacyMember2021-01-012021-09-300001402479medavail:MedCenterMember2022-07-012022-09-300001402479medavail:MedCenterMember2021-07-012021-09-300001402479medavail:MedCenterMember2022-01-012022-09-300001402479medavail:MedCenterMember2021-01-012021-09-300001402479us-gaap:MachineryAndEquipmentMember2022-01-012022-09-300001402479us-gaap:MachineryAndEquipmentMember2022-09-300001402479us-gaap:MachineryAndEquipmentMember2021-12-310001402479us-gaap:TechnologyEquipmentMembersrt:MinimumMember2022-01-012022-09-300001402479us-gaap:TechnologyEquipmentMembersrt:MaximumMember2022-01-012022-09-300001402479us-gaap:TechnologyEquipmentMember2022-09-300001402479us-gaap:TechnologyEquipmentMember2021-12-310001402479us-gaap:LeaseholdImprovementsMember2022-09-300001402479us-gaap:LeaseholdImprovementsMember2021-12-310001402479us-gaap:OtherMachineryAndEquipmentMembersrt:MinimumMember2022-01-012022-09-300001402479srt:MaximumMemberus-gaap:OtherMachineryAndEquipmentMember2022-01-012022-09-300001402479us-gaap:OtherMachineryAndEquipmentMember2022-09-300001402479us-gaap:OtherMachineryAndEquipmentMember2021-12-310001402479us-gaap:OfficeEquipmentMembersrt:MinimumMember2022-01-012022-09-300001402479srt:MaximumMemberus-gaap:OfficeEquipmentMember2022-01-012022-09-300001402479us-gaap:OfficeEquipmentMember2022-09-300001402479us-gaap:OfficeEquipmentMember2021-12-310001402479us-gaap:VehiclesMember2022-01-012022-09-300001402479us-gaap:VehiclesMember2022-09-300001402479us-gaap:VehiclesMember2021-12-310001402479us-gaap:ConstructionInProgressMember2022-09-300001402479us-gaap:ConstructionInProgressMember2021-12-310001402479us-gaap:IntellectualPropertyMember2022-09-300001402479us-gaap:IntellectualPropertyMember2021-12-310001402479us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-09-300001402479us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-310001402479medavail:WebsiteAndMobileApplicationMember2022-09-300001402479medavail:WebsiteAndMobileApplicationMember2021-12-31xbrli:pure0001402479us-gaap:SecuredDebtMembermedavail:SVBTermLoanMember2022-09-300001402479us-gaap:SecuredDebtMembermedavail:SVBTermLoanMember2021-12-310001402479us-gaap:SecuredDebtMemberus-gaap:PrimeRateMembermedavail:SVBTermLoanMember2022-01-012022-09-3000014024792022-06-1400014024792022-06-130001402479us-gaap:PrivatePlacementMember2022-03-30medavail:closing0001402479medavail:WarrantSharesMember2022-03-300001402479srt:MinimumMember2022-03-012022-03-310001402479srt:MaximumMember2022-03-012022-03-310001402479us-gaap:PrivatePlacementMember2022-04-042022-04-0400014024792022-08-1200014024792022-08-122022-08-120001402479us-gaap:EmployeeStockMember2022-07-012022-09-300001402479us-gaap:EmployeeStockMember2022-01-012022-09-300001402479us-gaap:RestrictedStockUnitsRSUMember2022-09-300001402479us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001402479us-gaap:RestrictedStockUnitsRSUMember2021-12-310001402479medavail:A2022InducementEquityIncentivePlanMember2022-04-3000014024792022-04-082022-04-080001402479us-gaap:RestrictedStockUnitsRSUMember2022-04-082022-04-080001402479us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-04-082022-04-080001402479medavail:WarrantsIssuedApril042022ExercisePriceMember2022-01-012022-09-300001402479medavail:WarrantsIssuedApril042022ExercisePriceMember2022-09-300001402479medavail:WarrantsIssuedJuly012022ExercisePriceMember2022-01-012022-09-300001402479medavail:WarrantsIssuedJuly012022ExercisePriceMember2022-09-300001402479us-gaap:InvestorMember2022-09-300001402479us-gaap:RestrictedStockUnitsRSUMembermedavail:A2022InducementEquityIncentivePlanMember2022-04-082022-04-080001402479us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-04-082022-04-080001402479medavail:WarrantsCallableAtTwelveMonthsMembermedavail:WarrantSharesMember2022-03-300001402479medavail:WarrantsCallableAtTwentyFourMonthsMembermedavail:WarrantSharesMember2022-03-30medavail:segment0001402479medavail:RetailPharmacyMembermedavail:RetailPharmacyServicesSegmentMember2022-07-012022-09-300001402479medavail:RetailPharmacyMembermedavail:PharmacyTechnologySegmentMember2022-07-012022-09-300001402479medavail:RetailPharmacyMember2022-07-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:HardwareMember2022-07-012022-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:HardwareMember2022-07-012022-09-300001402479medavail:HardwareMember2022-07-012022-09-300001402479medavail:SubscriptionRevenueMembermedavail:RetailPharmacyServicesSegmentMember2022-07-012022-09-300001402479medavail:SubscriptionRevenueMembermedavail:PharmacyTechnologySegmentMember2022-07-012022-09-300001402479medavail:SubscriptionRevenueMember2022-07-012022-09-300001402479medavail:PharmacyAndHardwareMembermedavail:RetailPharmacyServicesSegmentMember2022-07-012022-09-300001402479medavail:PharmacyAndHardwareMembermedavail:PharmacyTechnologySegmentMember2022-07-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:SoftwareMember2022-07-012022-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:SoftwareMember2022-07-012022-09-300001402479medavail:SoftwareMember2022-07-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:MaintenanceAndSupportMember2022-07-012022-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:MaintenanceAndSupportMember2022-07-012022-09-300001402479medavail:MaintenanceAndSupportMember2022-07-012022-09-300001402479medavail:InstallationMembermedavail:RetailPharmacyServicesSegmentMember2022-07-012022-09-300001402479medavail:InstallationMembermedavail:PharmacyTechnologySegmentMember2022-07-012022-09-300001402479medavail:InstallationMember2022-07-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:ProfessionalServicesMember2022-07-012022-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:ProfessionalServicesMember2022-07-012022-09-300001402479medavail:ProfessionalServicesMember2022-07-012022-09-300001402479us-gaap:ServiceMembermedavail:RetailPharmacyServicesSegmentMember2022-07-012022-09-300001402479us-gaap:ServiceMembermedavail:PharmacyTechnologySegmentMember2022-07-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMember2022-07-012022-09-300001402479medavail:PharmacyTechnologySegmentMember2022-07-012022-09-300001402479medavail:RetailPharmacyMembermedavail:RetailPharmacyServicesSegmentMember2021-07-012021-09-300001402479medavail:RetailPharmacyMembermedavail:PharmacyTechnologySegmentMember2021-07-012021-09-300001402479medavail:RetailPharmacyMember2021-07-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:HardwareMember2021-07-012021-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:HardwareMember2021-07-012021-09-300001402479medavail:HardwareMember2021-07-012021-09-300001402479medavail:SubscriptionRevenueMembermedavail:RetailPharmacyServicesSegmentMember2021-07-012021-09-300001402479medavail:SubscriptionRevenueMembermedavail:PharmacyTechnologySegmentMember2021-07-012021-09-300001402479medavail:SubscriptionRevenueMember2021-07-012021-09-300001402479medavail:PharmacyAndHardwareMembermedavail:RetailPharmacyServicesSegmentMember2021-07-012021-09-300001402479medavail:PharmacyAndHardwareMembermedavail:PharmacyTechnologySegmentMember2021-07-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:SoftwareMember2021-07-012021-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:SoftwareMember2021-07-012021-09-300001402479medavail:SoftwareMember2021-07-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:MaintenanceAndSupportMember2021-07-012021-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:MaintenanceAndSupportMember2021-07-012021-09-300001402479medavail:MaintenanceAndSupportMember2021-07-012021-09-300001402479medavail:InstallationMembermedavail:RetailPharmacyServicesSegmentMember2021-07-012021-09-300001402479medavail:InstallationMembermedavail:PharmacyTechnologySegmentMember2021-07-012021-09-300001402479medavail:InstallationMember2021-07-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:ProfessionalServicesMember2021-07-012021-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:ProfessionalServicesMember2021-07-012021-09-300001402479medavail:ProfessionalServicesMember2021-07-012021-09-300001402479us-gaap:ServiceMembermedavail:RetailPharmacyServicesSegmentMember2021-07-012021-09-300001402479us-gaap:ServiceMembermedavail:PharmacyTechnologySegmentMember2021-07-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMember2021-07-012021-09-300001402479medavail:PharmacyTechnologySegmentMember2021-07-012021-09-300001402479medavail:RetailPharmacyMembermedavail:RetailPharmacyServicesSegmentMember2022-01-012022-09-300001402479medavail:RetailPharmacyMembermedavail:PharmacyTechnologySegmentMember2022-01-012022-09-300001402479medavail:RetailPharmacyMember2022-01-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:HardwareMember2022-01-012022-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:HardwareMember2022-01-012022-09-300001402479medavail:HardwareMember2022-01-012022-09-300001402479medavail:SubscriptionRevenueMembermedavail:RetailPharmacyServicesSegmentMember2022-01-012022-09-300001402479medavail:SubscriptionRevenueMembermedavail:PharmacyTechnologySegmentMember2022-01-012022-09-300001402479medavail:SubscriptionRevenueMember2022-01-012022-09-300001402479medavail:PharmacyAndHardwareMembermedavail:RetailPharmacyServicesSegmentMember2022-01-012022-09-300001402479medavail:PharmacyAndHardwareMembermedavail:PharmacyTechnologySegmentMember2022-01-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:SoftwareMember2022-01-012022-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:SoftwareMember2022-01-012022-09-300001402479medavail:SoftwareMember2022-01-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:MaintenanceAndSupportMember2022-01-012022-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:MaintenanceAndSupportMember2022-01-012022-09-300001402479medavail:MaintenanceAndSupportMember2022-01-012022-09-300001402479medavail:InstallationMembermedavail:RetailPharmacyServicesSegmentMember2022-01-012022-09-300001402479medavail:InstallationMembermedavail:PharmacyTechnologySegmentMember2022-01-012022-09-300001402479medavail:InstallationMember2022-01-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:ProfessionalServicesMember2022-01-012022-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:ProfessionalServicesMember2022-01-012022-09-300001402479medavail:ProfessionalServicesMember2022-01-012022-09-300001402479us-gaap:ServiceMembermedavail:RetailPharmacyServicesSegmentMember2022-01-012022-09-300001402479us-gaap:ServiceMembermedavail:PharmacyTechnologySegmentMember2022-01-012022-09-300001402479medavail:RetailPharmacyServicesSegmentMember2022-01-012022-09-300001402479medavail:PharmacyTechnologySegmentMember2022-01-012022-09-300001402479medavail:RetailPharmacyMembermedavail:RetailPharmacyServicesSegmentMember2021-01-012021-09-300001402479medavail:RetailPharmacyMembermedavail:PharmacyTechnologySegmentMember2021-01-012021-09-300001402479medavail:RetailPharmacyMember2021-01-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:HardwareMember2021-01-012021-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:HardwareMember2021-01-012021-09-300001402479medavail:HardwareMember2021-01-012021-09-300001402479medavail:SubscriptionRevenueMembermedavail:RetailPharmacyServicesSegmentMember2021-01-012021-09-300001402479medavail:SubscriptionRevenueMembermedavail:PharmacyTechnologySegmentMember2021-01-012021-09-300001402479medavail:SubscriptionRevenueMember2021-01-012021-09-300001402479medavail:PharmacyAndHardwareMembermedavail:RetailPharmacyServicesSegmentMember2021-01-012021-09-300001402479medavail:PharmacyAndHardwareMembermedavail:PharmacyTechnologySegmentMember2021-01-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:SoftwareMember2021-01-012021-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:SoftwareMember2021-01-012021-09-300001402479medavail:SoftwareMember2021-01-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:MaintenanceAndSupportMember2021-01-012021-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:MaintenanceAndSupportMember2021-01-012021-09-300001402479medavail:MaintenanceAndSupportMember2021-01-012021-09-300001402479medavail:InstallationMembermedavail:RetailPharmacyServicesSegmentMember2021-01-012021-09-300001402479medavail:InstallationMembermedavail:PharmacyTechnologySegmentMember2021-01-012021-09-300001402479medavail:InstallationMember2021-01-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMembermedavail:ProfessionalServicesMember2021-01-012021-09-300001402479medavail:PharmacyTechnologySegmentMembermedavail:ProfessionalServicesMember2021-01-012021-09-300001402479medavail:ProfessionalServicesMember2021-01-012021-09-300001402479us-gaap:ServiceMembermedavail:RetailPharmacyServicesSegmentMember2021-01-012021-09-300001402479us-gaap:ServiceMembermedavail:PharmacyTechnologySegmentMember2021-01-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMember2021-01-012021-09-300001402479medavail:PharmacyTechnologySegmentMember2021-01-012021-09-300001402479medavail:RetailPharmacyServicesSegmentMemberus-gaap:OperatingSegmentsMember2022-09-300001402479medavail:PharmacyTechnologySegmentMemberus-gaap:OperatingSegmentsMember2022-09-300001402479us-gaap:CorporateNonSegmentMember2022-09-300001402479medavail:RetailPharmacyServicesSegmentMemberus-gaap:OperatingSegmentsMember2021-12-310001402479medavail:PharmacyTechnologySegmentMemberus-gaap:OperatingSegmentsMember2021-12-310001402479us-gaap:CorporateNonSegmentMember2021-12-310001402479country:US2022-09-300001402479country:US2021-12-310001402479country:CA2022-09-300001402479country:CA2021-12-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to_____
Commission File Number 001-36533

MEDAVAIL HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware90-0772394
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
4720 East Cotton Gin Loop, Suite 220, Phoenix, Arizona
85040
(Address of principal executive offices)(Zip Code)
+1 (905) 812-0023
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareMDVLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 8, 2022, there were 80,045,696 shares of the registrant’s common stock outstanding.
1




MedAvail Holdings, Inc.
Form 10-Q
For the Three and Nine Months Ended September 30, 2022

TABLE OF CONTENTS

Page
PART I
Item 1.Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Operations and Comprehensive Loss 6
Condensed Consolidated Statements of Shareholders' Equity 7
Condensed Consolidated Statements of Cash Flows 8
Notes to Condensed Consolidated Financial Statements
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3.Quantitative and Qualitative Disclosures about Market Risk
Item 4.Controls and Procedures
PART II
Item 1.Legal Proceedings
Item 1A.Risk Factors
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.Defaults Upon Senior Securities
Item 4.Mine Safety Disclosures
Item 5.Other Information
Item 6.Exhibits
Signatures


2

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.
These forward-looking statements include, but are not limited to, statements about:
•our plans to modify our current products, or develop new products;
•the expected growth of our business and organization;
•our expectations regarding the size of our sales organization and expansion of our sales and marketing efforts;
•our ability to retain and recruit key personnel, including the continued development of a sales and marketing infrastructure;
•our ability to obtain and maintain intellectual property protection for our products;
•our ability to expand our business into new geographic markets;
•our compliance with extensive Nasdaq requirements and government laws, rules and regulations both in the United States and internationally;
•our estimates of expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing;
•our ability to identify and develop new and planned products and/or acquire new products;
•the expectations regarding the impact of the COVID-19 pandemic on our business;
•existing regulations and regulatory developments in the United States, Canada and other jurisdictions;
•the impact of laws and regulations;
•our financial performance;
•the period over which we estimate our existing cash, cash equivalents and available-for-sale investments will be sufficient to fund our future operating expenses and capital expenditure requirements;
•our anticipated use of our existing resources;
•developments and projections relating to our competitors or our industry; and
•the impact of general market and macroeconomic conditions, including inflation and events including the outbreak of war in Ukraine,
on our business.

We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
3

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.
You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the SEC as exhibits to the Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

4

PART I
Item 1. Financial Statements
MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands, except share amounts)

September 30,December 31,
20222021
Assets
Current assets:
Cash and cash equivalents$27,196 $19,689 
Restricted cash676 400 
Accounts receivable (net of allowance for doubtful accounts of $186 thousand for September 30, 2022, $66 thousand for December 31, 2021)
2,262 1,189 
Inventories6,401 3,916 
Prepaid expenses and other current assets2,863 2,191 
Total current assets39,398 27,385 
Property, plant and equipment, net6,370 5,692 
Intangible assets, net1,580 2,300 
Right-of-use assets2,270 2,538 
Other assets233 228 
Total assets$49,851 $38,143 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$2,006 $2,477 
Accrued liabilities1,383 1,530 
Accrued payroll and benefits2,869 2,733 
Deferred revenue70 83 
Current portion of lease obligations728 682 
Total current liabilities7,056 7,505 
Long-term debt, net9,751 9,538 
Long-term portion of lease obligations
1,738 2,027 
Total liabilities18,545 19,070 
Commitments and contingencies
Stockholders' equity:
Common shares ($0.001 par value, 300,000,000 shares authorized, 80,045,696 and 32,902,048 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively)
80 33 
Warrants
11,148 1,373 
Additional paid-in-capital255,642 216,685 
Accumulated other comprehensive loss(6,928)(6,928)
Accumulated deficit(228,636)(192,090)
Total stockholders' equity31,306 19,073 
Total liabilities and stockholders' equity$49,851 $38,143 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(in thousands, except share and per-share amounts)


Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Revenue:
Pharmacy and hardware revenue$11,266 $5,659 $31,210 $14,165 
Service revenue195 133 549 684 
Total revenue11,461 5,792 31,759 14,849 
Cost of products sold and services:
Pharmacy and hardware cost of products sold10,113 5,539 28,827 13,744 
Service costs56 67 221 426 
Total cost of products sold and services10,169 5,606 29,048 14,170 
Operating expense:
Pharmacy operations4,392 3,750 11,970 9,428 
General and administrative6,087 5,320 18,729 16,733 
Selling and marketing2,126 1,909 6,738 5,056 
Research and development178 232 952 601 
Total operating expense12,783 11,211 38,389 31,818 
Operating loss(11,491)(11,025)(35,678)(31,139)
Other gain (loss), net— 7 — 206 
Interest income— 7 1 74 
Interest expense(315)(260)(845)(328)
Loss before income taxes(11,806)(11,271)(36,522)(31,187)
Income tax expense— (2)(24)(2)
Net loss and comprehensive loss$(11,806)$(11,273)$(36,546)$(31,189)
Net loss per share - basic and diluted$(0.15)$(0.34)$(0.60)$(0.96)
Weighted average shares outstanding - basic and diluted80,045,99532,750,83160,947,51132,580,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Statements of Shareholders' Equity
(Unaudited)
(in thousands, except per share amounts)

Common Shares
Preferred Shares (1)
WarrantsAdditional Paid-in-CapitalAccumulated DeficitAccumulated Other Comprehensive LossTotal Stockholders' Equity
SharesAmountSharesAmount
Balance at June 30, 202270,609,972 $71 — $— $8,876 $247,598 $(216,830)$(6,928)$32,787 
Net loss— — — — — — (11,806)— (11,806)
Issuance of common shares 9,411,765 9 — — — 9,751 — — 9,760 
Issuance of warrants — — — — 2,272 (2,272)— — — 
Shares issued for vested restricted stock units23,959 — — — — — — — — 
Share-based compensation— — — — — 565 — — 565 
Balance at September 30, 2022
80,045,696 $80 — $— $11,148 $255,642 $(228,636)$(6,928)$31,306 
Balance at December 31, 2021
32,902,048 $33 — — $1,373 $216,685 $(192,090)$(6,928)$19,073 
Net loss— — — — — — (36,546)— (36,546)
Issuance of common shares 47,058,820 47 — — — 46,914 — — 46,961 
Issuance of warrants — — — — 9,775 (9,775)— — — 
Shares issued for vested restricted stock units30,833 — — — — — — — — 
Issuance of common shares under employee stock purchase plan53,995 — — — — 77 — — 77 
Share-based compensation— — — — — 1,741 — — 1,741 
Balance at September 30, 2022
80,045,696 $80 — $— $11,148 $255,642 $(228,636)$(6,928)$31,306 
Balance at June 30, 202132,583,734$33 —$— $1,485 $215,700 $(168,191)$(6,928)$42,099 
Net loss—— —— — — (11,273)— (11,273)
Exercise of warrants171,191— —— (112)139 — — 27 
Share-based compensation—— —— — 365 — — 365 
Balance at September 30, 2021
32,754,925$33 —$— $1,373 $216,204 $(179,464)$(6,928)$31,218 
Balance at December 31, 2020
31,816,02032 —— 2,614 213,624 (148,275)(6,928)61,067 
Net loss—— —— — — (31,189)— (31,189)
Exercise of options144,101— —— — 241 — — 241 
Exercise of warrants794,8041 —— (1,241)1,391 — — 151 
Share-based compensation—— —— — 948 — — 948 
Balance at September 30, 2021
32,754,925$33 —$— $1,373 $216,204 $(179,464)$(6,928)$31,218 

(1) $0.001 par value, 10,000,000 shares authorized for all periods presented.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Nine Months Ended September 30,
20222021
Cash flows from operating activities:
Net loss$(36,546)$(31,189)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment891 928 
Amortization of intangible and leased assets2,141 877 
Bad debt and other non-cash receivables adjustments120 47 
Term loan discount amortization and interest accretion on debt213 — 
Impairment of lease asset(27)— 
Share-based compensation expense1,741 948 
PPP loan forgiveness gain— (161)
Changes in operating assets and liabilities:
Accounts receivable(1,193)398 
Inventory(3,354)(2,511)
Prepaid expenses and other current assets(672)772 
Accounts payable, accrued expenses and other liabilities(137)2,180 
Deferred revenue(13)42 
Operating lease liability due to cash payments(447)(505)
Net cash used in operating activities(37,283)(28,174)
Cash flows from investing activities:
Purchase of property, plant and equipment(804)(680)
Payment of security deposits(5)(45)
Purchase of intangible and other assets(1,088)(1,544)
Net cash used in investing activities(1,897)(2,269)
Cash flows from financing activities:
Proceeds from issuance of common shares, net46,961 — 
Proceeds from issuance of common shares upon exercise of options and warrants— 392 
Proceeds from issuance of common shares upon exercise of employee stock purchase plan77 — 
Proceeds from debt— 10,000 
Payment of debt issuance costs— (624)
Repayment of debt— (1,000)
Payments on finance lease obligations
(75)(46)
Net cash provided by financing activities46,963 8,722 
Net increase (decrease) in cash, cash equivalents and restricted cash7,783 (21,721)
Cash, cash equivalents and restricted cash at beginning of period20,089 57,996 
Cash, cash equivalents and restricted cash at end of period$27,872 $36,275 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8


MEDAVAIL HOLDINGS, INC.
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(in thousands)
Nine Months Ended September 30,
20222021
Supplemental cash flow information:
    Cash paid for interest$603 $125 
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment$869 $1,075 
Property, plant and equipment transferred to intangible assets$— $46 
Purchase of property, plant and equipment in accounts payable$21 $56 
Purchase of intangible assets in accounts payable$— $398 
Fair value of warrants issued upon closing of private placement$9,775 $— 
Lease liabilities arising from obtaining right of use assets:
Operating leases$206 $2,177 
Finance leases$73 $97 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
9



MEDAVAIL HOLDINGS, INC.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
NOTE 1 - NATURE OF OPERATIONS
MedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation formerly known as MYOS RENS Technology, is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter facilitates live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. The Company also operates SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing the Company’s automated pharmacy technology.

NOTE 2 - GOING CONCERN
Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to the Company's ability to continue as a going concern. If substantial doubt does exist, then management should determine if there are plans in place which alleviate that doubt. Since inception through September 30, 2022, the Company has continually incurred losses from operations which have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. Net cash used in operating activities for nine months ended September 30, 2022 and 2021 was $37.3 million and $28.2 million, respectively. As of September 30, 2022, the Company had $27.2 million in cash and cash equivalents and an accumulated deficit of $228.6 million.

In April 2022, the Company completed a private placement, pursuant to which the Company received $40.0 million in gross proceeds, with an additional $10.0 million in gross proceeds received upon the second close that occurred on July 1, 2022, before deducting placement agent commissions and other offering expenses totaling $3.0 million. Additionally, the private placement included warrants, some of which may be callable at the Company’s option beginning on each of the 12 month and 24 month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. See Note 11 for further information regarding the private placement warrants.

Due to the Company’s significant and ongoing cash requirements to fund operations, management determined that there is substantial doubt as to the Company’s ability to continue as a going concern. The Company added liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank as described in Note 8, pursuant to which the Company borrowed $10.0 million in aggregate initial term loans. Additionally, as referenced above, the Company raised $40.0 million and $10.0 million in gross proceeds through a private placement that closed in April 2022 and July 2022, respectively. There can be no assurance that the steps management is taking will be successful. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, the Company may have to significantly reduce operations or delay, scale back or discontinue development and expansion plans. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on continued development and deployment of MedCenter kiosks and SpotRx pharmacy operations and the ability to raise significant additional funding.

NOTE 3 - BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements as of September 30, 2022 and for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information and in accordance with the rules of the Securities and Exchange Commission ("SEC") applicable to interim reports of companies filing as a smaller reporting company. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The condensed consolidated balance sheet as of December 31, 2021 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 29, 2022, or the 2021 Form 10-K.
The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for,
10

among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, and impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are deemed to be necessary.
Risks and uncertainties relating to COVID-19
The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact the Company's clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of September 30, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s condensed consolidated financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results could differ from these estimates and any such differences may be material to the Company’s financial statements.
Principles of consolidation
The unaudited condensed consolidated financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.
Reclassifications
During the fourth quarter of 2021, management reclassified certain operating expenses to reflect the costs attributable to pharmacy operations. Specifically, certain costs were reclassified from general and administrative expenses, to pharmacy operations expenses and selling and marketing expenses. This reclassification had no impact on the operating loss subtotal within the consolidated statements of operations and comprehensive loss. The effect of the reclassifications within the condensed consolidated statement of operations and comprehensive loss for 2021 are as follows (in thousands):
Three Months Ended September 30, 2021
Current presentationAs previously reportedChange
Pharmacy operations$3,750 $2,395 $1,355 
General and administrative5,320 6,805 (1,485)
Selling and marketing1,909 1,779 130 
$10,979 $10,979 $— 

Nine Months Ended September 30, 2021
Current presentationAs previously reportedChange
Pharmacy operations$9,428 $6,619 $2,809 
General and administrative16,733 19,941 (3,208)
Selling and marketing5,056 4,657 399 
$31,217 $31,217 $— 



11

NOTE 4 - RECENT ACCOUNTING PRONOUNCEMENTS
Measurement of Credit Losses on Financial Statements
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. ASU No. 2016-13 will be effective beginning in the first quarter of the Company's fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures.
In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820)”- Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, (“ASU 2022-03”). The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements.

Recently Adopted Accounting Standards
There was no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s condensed consolidated financial statements through the reporting date.

NOTE 5 - EARNINGS (LOSS) PER SHARE
Basic earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period.
The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period from the date of issuance to the exercise date. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding:
SharesIssuance DateExercise Date
118,228May 9, 2018May 10, 2021
309,698February 11, 2020May 10, 2021
84,911June 29, 2020May 10, 2021
39,208November 18, 2020May 10, 2021
19,310November 18, 2020Outstanding
During the three and nine months ended September 30, 2022 and 2021, there was no dilutive effect from stock options or other warrants due to the Company’s net loss position. As of September 30, 2022 and 2021, there were 4.5 million and 2.9 million, respectively, of option awards outstanding that were not included in the diluted shares calculation because their inclusion would have been antidilutive. As of September 30, 2022 and December 31, 2021, there were 24.3 million and 0.7 million, respectively, of unexercised warrants that were not included in the diluted shares calculation.

12

NOTE 6 - FAIR VALUE MEASUREMENTS
Assets and liabilities measured at fair value on a recurring basis were as follows:
Fair Value Hierarchy
(in thousands)September 30, 2022Level 1Level 2Level 3
Assets:
Cash and cash equivalents$27,196 $27,196 $— $— 
Restricted cash676 676 — — 
Total assets$27,872 $27,872 $— $— 
Fair Value Hierarchy
(in thousands)December 31, 2021Level 1Level 2Level 3
Assets:
Cash and cash equivalents$19,689 $19,689 $— $— 
Restricted cash400 400 — — 
Total assets$20,089 $20,089 $— $— 
The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to us for debt of similar risk and maturities. Refer to Note 8, Debt, for further information.

NOTE 7 - BALANCE SHEET AND OTHER INFORMATION
Restricted cash

The Company considers cash to be restricted when withdrawal or general use is legally restricted. During the nine months ended September 30, 2022, the Company recovered the $0.1 million restricted cash balance outstanding at December 31, 2021, that was held as a guarantee for certain purchasing cards. During the same period, pursuant to a Loan and Security Agreement with Silicon Valley Bank dated June 7, 2021 (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.7 million balance with the bank to secure the outstanding letters of credit, of which $0.3 million was issued in February 2022. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in the balance for cash, cash equivalents and restricted cash presented in the statements of cash flows.

Inventory
The following table presents detail of inventory balances:
September 30,December 31,
(in thousands)20222021
Inventory:
MedCenter hardware$2,464 $1,201 
Pharmaceuticals3,275 2,150 
Spare parts662 565 
Total inventory$6,401 $3,916 
Pharmaceutical inventory was recognized in pharmacy and hardware cost of products sold at $9.3 million and $5.0 million during the three months ended September 30, 2022 and 2021, respectively, and $26.4 million and $12.2 million during the nine months ended September 30, 2022 and 2021, respectively. MedCenter hardware was recognized in pharmacy and hardware cost of products sold at $0.01 million and $0.1 million during the three months ended September 30, 2022 and 2021, respectively, and $0.2 million and $0.5 million during the nine months ended September 30, 2022 and 2021, respectively.
13

Prepaid expenses and other current assets

The following table presents prepaid expenses and other current assets balances:
September 30,December 31,
(in thousands)20222021
Prepaid expenses and other current assets:
Prepaid MedCenter inventory$2,204 $1,050 
Prepaid insurance292 509 
Other367 632 
Total prepaid expenses and other current assets$2,863 $2,191 

Property, plant and equipment, net
The following table presents property, plant and equipment balances:
Estimated useful livesSeptember 30,December 31,
(in thousands)20222021
Property, plant and equipment:
MedCenter equipment
8 years
$7,525 $5,875 
IT equipment
1 - 3 years
2,390 2,361 
Leasehold improvementslesser of useful life or term of lease980 880 
General plant and equipment
5 - 8 years
619 603 
Office furniture and equipment
5 - 8 years
538 394 
Vehicles
5 years
54 54 
Construction-in-process481 1,021 
Total historical cost12,587 11,188 
Accumulated depreciation(6,217)(5,496)
Total property, plant and equipment, net$6,370 $5,692 
Depreciation expense of property and equipment was $0.3 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, and $0.9 million and $0.9 million for the nine months ended September 30, 2022 and 2021, respectively. Depreciation expense included in pharmacy and hardware cost of products sold was $0.03 million and $0.05 million for the three months ended September 30, 2022 and 2021, respectively, and $0.1 million and $0.1 million for the nine months ended September 30, 2022, and 2021, respectively.
14

Intangible assets, net
The following table presents intangible asset balances:
September 30,December 31,
(in thousands)20222021
Gross intangible assets:
Intellectual property$3,857 $3,857 
Software5,321 4,475 
Website and mobile application583 583 
Total intangible assets9,761 8,915 
Accumulated amortization:
Intellectual property(3,857)(3,857)
Software(3,741)(2,175)
Website and mobile application(583)(583)
Total accumulated amortization(8,181)(6,615)
Total intangible assets, net$1,580 $2,300 
No intangible assets were purchased for the three months ended September 30, 2022. The Company purchased $0.7 million of intangible assets for the three months ended September 30, 2021, and $0.9 million and $1.9 million for the nine months ended September 30, 2022 and 2021, respectively.
Amortization expense of intangible assets was $1.3 million and $0.1 million for the three months ended September 30, 2022 and 2021, respectively, and $1.6 million and $0.2 million for the nine months ended September 30, 2022 and 2021, respectively, and are included in operating expenses.
The Company’s management team is evaluating its existing systems and software. If management were to determine that certain systems or software were to be replaced in order to achieve greater efficiencies, cost savings, or both, the estimated remaining useful life of some IT equipment and intangible assets may be reduced, resulting in higher depreciation and amortization expense, respectively.

Lessee leases
Balance sheet amounts for lease assets and leases liabilities are as follows:
September 30,December 31,
(in thousands)20222021
Assets:
Operating$2,110$2,376
Finance160162
Total assets$2,270$2,538
Liabilities:
Operating:
Current$632 $599 
Long-term1,673 1,947 
Finance:
Current96 83 
Long-term65 80 
Total liabilities$2,466 $2,709 
15

The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows:
September 30,December 31,
(in thousands)20222021
Operating leases:
Weighted-average remaining lease term (years)3.84.2
Weighted-average discount rate6.9 %6.9 %
Finance leases:
Weighted-average remaining lease term (years)1.81.5
Weighted-average discount rate8.6 %8.8 %
Maturities of operating leases liabilities as of September 30, 2022, are as follows, in thousands:
Remaining period in 2022$202 
2023755 
2024617 
2025534 
2026468 
202764 
Thereafter— 
Total lease payments2,640 
Less: present value discount(335)
Total leases$2,305 
Maturities of finance lease liabilities as of September 30, 2022, are as follows, in thousands:
Remaining period in 2022$30 
202391 
202449 
20254 
Thereafter— 
Total finance lease payments174 
Less: imputed interest(13)
Total leases$161 
Operating lease expenses were $0.2 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, and $0.7 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively.


16

NOTE 8 - DEBT
The following table presents debt balances:
September 30,December 31,
(in thousands)20222021
Term loan10,162 10,070 
Term loan issuance costs, net(411)(532)
Total long-term debt, net$9,751 $9,538 
Term loan
The term loan bears interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% (10.25% at September 30, 2022). The term loan matures on April 1, 2026. Principal repayment will commence on May 1, 2024 in equal monthly installments of the outstanding loan balance through the maturity date.

NOTE 9 - INCOME TAXES
The Company incurred $0.02 million and zero of income tax expense for the nine months ended September 30, 2022, and 2021, respectively. The income taxes for the periods ended September 30, 2022, are primarily attributed to certain state taxes. The Company continues to be in a loss position as of September 30, 2022. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses.

As of September 30, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the foreseeable future.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, implements a 15% minimum tax on book income of certain large corporations, a 1% excise tax on net stock repurchases and several tax incentives to promote clean energy. The Company has evaluated the impacts of this legislation to the financial statements but does not expect them to be material.

NOTE 10 - COMMITMENTS AND CONTINGENCIES
Legal
Following MYOS Rens Technology Inc.’s, or MYOS’s and MedAvail, Inc.’s, or MAI's, announcement of the execution of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation.
The Demands and the Complaints that comprised the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties.
MYOS and MAI believe that the claims asserted in the Litigation were without merit, and believe that the Form S-4 Registration Statement disclosed all material information concerning the Merger and no supplemental disclosure was required under applicable law. However, in order to avoid the risk of the Litigation delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, MYOS determined to voluntarily supplement the Form S-4 Registration Statement as described in the Current Report on Form 8-K on November 2, 2020. Subsequently, the Nevada Complaint and the New York Complaint were voluntarily dismissed. MYOS and MAI specifically deny all allegations in the Litigation and/or that any additional disclosure was or is required, and none of the Litigation remains currently pending.

17

NOTE 11 - EQUITY, SHARE-BASED COMPENSATION AND WARRANTS
On June 14, 2022, the Company’s stockholders approved an Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock, par value $0.001, from 100 million shares to a new total of 300 million shares. The Restated Certificate was effective upon filing the Restated Certificate with the Secretary of State of the State of Delaware on June 15, 2022.
Private Placement
On March 30, 2022, the Company entered into a Securities Purchase Agreement, or Purchase Agreement, with certain purchasers thereto, or the Investors. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investors in a private placement, or the Private Placement, up to 47.1 million shares, or the Shares, of the Company’s common stock, and to issue warrants, or the Warrants, to purchase up to 23.5 million shares of common stock, or Warrant Shares. The Shares and the Warrants were sold at two closings as further described below, at a price per share of $1.0625.
Each Investor purchasing Shares in the Private Placement was issued a Warrant to purchase that number of Warrant Shares equal to 50% of the number of Shares purchased under the Purchase Agreement by such Investor. The Warrants have a per share exercise price of $1.25 and will be exercisable by the holder at any time on or after the issuance date of the Warrant for a period of five years. If the Warrants were exercised in full immediately after issuance by the Investors, the Company would receive additional gross proceeds of up to $29.4 million. In addition, the Warrant terms provide the Company with a call option to force the Warrant holders to exercise up to two-thirds of the warrant shares subject to each Warrant, with one-third of the Warrant Shares being callable beginning on each of the 12 month and 24 month anniversaries of the Warrant issuance dates, in each case until the expiration of the Warrants, and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. If the Company were to exercise the contingent call options immediately after issuance, approximately $19.6 million in gross proceeds could be raised.
On April 4, 2022, the first closing of the Private Placement occurred, in which 37.6 million shares of common stock for $40.0 million in gross proceeds, before deducting placement agent commissions and other offering expenses, and Warrants exercisable for up to 18.8 million Warrant Shares were issued by the Company. A second and final closing occurred on July 1, 2022, and the Investors purchased an additional 9.4 million shares of common stock for $10.0 million in additional gross proceeds and Warrants exercisable for up to 4.7 million Warrants Shares.
Shelf Registration and Sales Agreement

On August 12, 2022, the Company filed a shelf registration statement on Form S-3, or the Shelf, with the SEC in relation to the registration and potential future issuance of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, units and/or any combination thereof, in the aggregate amount of up to $150,000,000. The Shelf was declared effective on August 26, 2022. The Company also entered into a sales agreement as of August 12, 2022, or Sales Agreement, with Cowen and Company, LLC, or Cowen, as sales agent, providing for the offering, issuance and sale of up to an aggregate $50,000,000 of the Company’s common stock from time to time at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Nasdaq Capital Market or any other trading market for the Company’s common stock in “at-the-market” offerings, under the Shelf. As of September 30, 2022, the Company has not issued and sold any shares of common stock under the Sales Agreement.

Share-based compensation
The following table presents the Company's expense related to share-based compensation (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Share-based compensation$565 $365 $1,741 $948 
The share-based compensation expense for the three and nine months ended September 30, 2022 and included $0.02 million and $0.1 million, respectively, from employee stock purchase plan expense.
The expense remaining to be recognized for unvested option awards from the 2012, 2018, and 2020 plans and the 2022 inducement plan as of September 30, 2022 was $2.4 million, which is expected to be recognized on a weighted average basis over the next 2.7 years. The expense remaining to be recognized for unvested restricted stock units was $2.2 million, which will be recognized on a weighted average basis over the next 2.3 years.
18

The following table presents the Company's outstanding option awards activity during the nine months ended September 30, 2022:
(in thousands, except for share and per share amounts)Number of AwardsWeighted Average Exercise PriceWeighted Average Share Price on Date of ExerciseWeighted Average Fair ValueWeighted Average Remaining Contractual Life (Years)Aggregate Intrinsic Value
Outstanding, beginning of period2,848,903 $2.78 $1.44 $104 
Granted2,758,040 1.35 0.98 — 
Exercised/released— — — — 
Expired(117,730)1.99 1.08 5 
Forfeited(952,488)2.52 1.42 111 
Outstanding, end of period4,536,725 $1.93 $1.15 8.33$— 
Vested and exercisable, end of the period1,777,907 2.28 1.16 6.79— 
Vested and unvested exercisable, end of the period1,777,907 2.28 1.16 6.79— 
Vested and expected to vest, end of the period4,309,018 1.94 1.15 8.29— 

The following table presents the Company's outstanding restricted stock unit activity during the nine months ended September 30, 2022:

(in thousands, except for share and per share amounts)Number of AwardsWeighted Average Exercise PriceWeighted Average Share Price on Date of ExerciseWeighted Average Fair ValueWeighted Average Remaining Contractual Life (Years)Aggregate Intrinsic Value
Outstanding, beginning of period802,740 $— $2.78 $1,124 
Granted1,601,824 — 1.41 2,252 
Exercised/released(46,009)— $1.17 6.32 54 
Expired— — — — 
Forfeited(585,973)— 2.05 791 
Outstanding, end of period1,772,582 $— $1.69 4.93$1,376 
Vested and exercisable, end of the period— — — — 
Vested and unvested exercisable, end of the period— — — — 
Vested and expected to vest, end of the period1,628,975 — 1.69 4.921,264 

An aggregate of 2.8 million and 3.4 million shares of common stock was available for grant under the 2020 Plan as of September 30, 2022 and December 31, 2021, respectively.

In April 2022, the Company adopted the MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan or the Inducement Plan. The Inducement Plan reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 8, 2022, the Company issued inducement awards to employees that included options to purchase 426,500 shares of Company common stock, and 426,500 restricted stock units. The inducement stock options have an exercise price of $1.96, and 25% of the shares vest on the one year anniversary of the date that employment commenced, and an additional one forty-eighth (1/48th) of the shares vest monthly thereafter. The inducement restricted stock units vest at one-third (1/3rd) of the shares on the first, second and third yearly anniversaries of March 1, 2022.
Warrants
During the nine months ended September 30, 2022, 18.8 million warrants were issued from the first closing of the Private Placement in April 2022 with a fair value of $7.5 million. 4.7 million warrants were issued from the second closing of the Private Placement in July 2022 with a fair value of $2.3 million. No warrants were exercised during the nine months ended September 30, 2022. There were 24.2 million related party warrants outstanding as of September 30, 2022.
The terms for the warrants issued from the Private Placement were as follows:
19

September 30, 2022
Issue DateReason for issuanceTerm (years)Exercise Price (USD)
April 4, 2022Private Placement5$1.25 
July 1, 2022Private Placement5$1.25 

NOTE 12 - REVENUE AND SEGMENT REPORTING
Operating segments are the individual operations that the chief operating decision maker, or CODM, who is the Company's chief executive officer, reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The retail pharmacy services and pharmacy technology operating segments both engage in different business activities from which they earn revenues and incur expenses.
The Company has the following two reportable segments:
Retail Pharmacy Services Segment
Retail Pharmacy Services segment revenue consists of products sold directly to consumers at the point of sale. MedAvail recognizes retail pharmacy revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts.
Pharmacy Technology Segment
The Pharmacy Technology Segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sum payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements.
The following tables present revenue and costs of products sold and services by segment (in thousands):
20

Retail Pharmacy ServicesPharmacy TechnologyTotal
Three Months Ended September 30, 2022
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue$11,162 $— $11,162 
Hardware— — — 
Subscription— 104 104 
Total pharmacy and hardware revenue11,162 104 11,266 
Service revenue:
Software— 94 94 
Maintenance and support— 48 48 
Installation— — — 
Professional services and other— 53 53 
Total service revenue— 195 195 
Total revenue11,162 299 11,461 
Cost of products sold and services10,047 122 10,169 
Segment gross profit$1,115 $177 1,292 
Operating expense:
Pharmacy operations4,392 
General and administrative6,087 
Selling and marketing2,126 
Research and development178 
Total operating expense12,783 
Operating loss$(11,491)
21

Retail Pharmacy ServicesPharmacy TechnologyTotal
Three Months Ended September 30, 2021
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue$5,445 $— $5,445 
Hardware— 106 106 
Subscription— 108 108 
Total pharmacy and hardware revenue5,445 214 5,659 
Service revenue:
Software— 51 51 
Maintenance and support— 44 44 
Installation— 11 11 
Professional services and other— 27 27 
Total service revenue— 133 133 
Total revenue5,445 347 5,792 
Cost of products sold and services5,366 240 5,606 
Segment gross profit$79 $107 186 
Operating expense:
Pharmacy operations3,750 
General and administrative5,320 
Selling and marketing1,909 
Research and development232 
Total operating expense11,211 
Operating loss$(11,025)
22

Retail Pharmacy ServicesPharmacy TechnologyTotal
Nine Months Ended September 30, 2022
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue$30,652 $— $30,652 
Hardware— 236 236 
Subscription— 322 322 
Total pharmacy and hardware revenue30,652 558 31,210 
Service revenue:
Software— 228 228 
Maintenance and support— 127 127 
Installation— 77 77 
Professional services and other— 117 117 
Total service revenue— 549 549 
Total revenue30,652 1,107 31,759 
Cost of products sold and services28,460 588 29,048 
Segment gross profit$2,192 $519 2,711 
Operating expense:
Pharmacy operations11,970 
General and administrative18,729 
Selling and marketing6,738 
Research and development952 
Total operating expense38,389 
Operating loss$(35,678)


23

Retail Pharmacy ServicesPharmacy TechnologyTotal
Nine Months Ended September 30, 2021
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue$13,357 $— $13,357 
Hardware— 470 470 
Subscription— 338 338 
Total pharmacy and hardware revenue13,357 808 14,165 
Service revenue:
Software— 125 125 
Maintenance and support— 115 115 
Installation— 39 39 
Professional services and other— 405 405 
Total service revenue— 684 684 
Total revenue13,357 1,492 14,849 
Cost of products sold and services13,130 1,040 14,170 
Segment gross profit$227 $452 679 
Operating expense:
Pharmacy operations9,428 
General and administrative16,733 
Selling and marketing5,056 
Research and development601 
Total operating expense31,818 
Operating loss$(31,139)
The following table presents assets and liabilities by segment (in thousands):
Retail Pharmacy ServicesPharmacy TechnologyCorporateTotal
September 30, 2022
Assets$15,939 $7,953 $25,959 $49,851 
Liabilities$5,841 $2,689 $10,015 $18,545 
December 31, 2021
Assets$13,641 $5,222 $19,280 $38,143 
Liabilities$5,618 $3,567 $9,885 $19,070 
The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets (in thousands):
September 30,December 31,
20222021
Long-lived assets:
United States$8,286 $7,675 
Canada354 555 
Total long-lived assets$8,640 $8,230 


24

NOTE 13 – SUBSEQUENT EVENTS

Nasdaq Capital Market Listing Qualifications

The Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Capital Market (“Nasdaq”) on October 31, 2022 notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion in Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter will not result in the immediate delisting of the Company’s common stock from Nasdaq.

The Company has an initial period of 180 calendar days, or until May 1, 2023, to regain compliance with the Bid Price Rule. If the Company is not in compliance with the Bid Price Rule within the first 180 calendar days, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards required by Nasdaq, except for the minimum bid price requirement.

The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, including initiating a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule or will otherwise be in compliance with other Nasdaq Listing Rules. If we do not regain compliance with the Bid Price Rule and are not eligible for an additional compliance period, our common stock may be delisted. For more information, see “Risk Factors - Our share price does not meet the minimum bid price for continued listing on Nasdaq. Our ability to continue operations or to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we do not regain compliance with the minimum bid price requirement and we are delisted from Nasdaq.”
25

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion in conjunction with our audited historical condensed consolidated financial statements for the year ended December 31, 2021, which are included in the Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 29, 2022, and our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2022 included elsewhere in this Quarterly Report on Form 10-Q. This Management's Discussion and Analysis of Financial Condition and Results of Operations contains statements that are forward-looking. These statements are based on current expectations and assumptions that are subject to risks, uncertainties and other factors. Actual results could differ materially because of the factors discussed below or elsewhere in this Quarterly Report on Form 10-Q. See Part II, Item 1A. "Risk Factors" of this Quarterly Report on Form 10-Q, and Part I, Item 1A. "Risk Factors" of the 2021 Form 10-K for the year ended December 31, 2021. Unless otherwise indicated or the context otherwise requires, references herein to “MedAvail,” “MedAvail Holdings,” “we,” “us,” “our,” and the “Company” refers to MedAvail Holdings, Inc. and its subsidiaries.
Overview
We are a technology-enabled retail pharmacy technology and services company, we have developed and commercialized an innovative self-service pharmacy, mobile application, and kiosk. Through our full-stack pharmacy technology platform, and personal one-on-one service, we bring pharmacy-dispensing capability to the point of care, resulting in lower costs, higher patient satisfaction, improved medication adherence, and better health outcomes.
We offer a unique, pharmacy technology solution which is anchored around our core technology called the MedAvail MedCenter™, or the MedCenter. The MedCenter enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and any other location where onsite prescription dispensing is desired. The MedCenter establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient while still providing real-time supervision by a pharmacist. Although our technology platform has broad application, we are currently focused on serving high-value Medicare members in the United States of America, or U.S.
We currently deploy the MedCenter solution through two distinct commercialization channels. First, we own and operate a full retail pharmacy business in the U.S. under the name SpotRx™, or SpotRx. The SpotRx pharmacy business is structured as a hub-and-spoke model where a central pharmacy supports and operates MedCenter kiosks embedded in medical clinics, usually in close proximity to the central pharmacy. Second, as a direct ‘sell-to’ model, commercialization channel, we sell the MedCenter technology and subscriptions for the associated software directly to large healthcare providers and retailers for use within their own pharmacy operations.
The MedCenter kiosk works in tandem with our Remote Dispensing System®, or the Remote Dispensing System, which consists of customer-facing software for remote ordering of medications for pick-up at a MedCenter, or next day home delivery. Supporting our MedCenter kiosks and Remote Dispensing System are our back-end MedPlatform® Enterprise Software, or the MedPlatform Enterprise Software, which controls dispensing and MedCenter monitoring, and supporting Pharmacy Management System software, which allows connection to our supporting team of pharmacists and kiosk administrators.
Traditional retail pharmacies are built around a physical store front. In order to dispense medication, these stores must have a pharmacist onsite for all hours of operation. Many pharmacies have reduced hours of operation based on customer purchasing patterns in order to contain labor cost, which results in further reduced consumer access. Furthermore, retail pharmacy wait times are typically 30 to 60 minutes or more, causing substantial delays for the consumer. During the COVID-19 pandemic, many people are looking to minimize the amount of physical contact that can lead to further disease contraction, especially for those most vulnerable, such as the elderly or those with compromised immune systems. Consequently, some patients are foregoing filling their prescribed medications, leading to declining health, increased healthcare costs and increased morbidity.
Components of Operating Results for the Nine Months Ended September 30, 2022
We have never been profitable and we incurred operating losses each year since inception. Our net losses were $36.5 million and $31.2 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, we had an accumulated deficit of $228.6 million. Substantially all of our operating losses resulted from expenses incurred in connection with building out our retail pharmacy services operating footprint and from general and administrative costs associated with our operations.
We expect to incur significant additional expenses and operating losses for the foreseeable future as we initiate and continue the technology development, deployment of our MedCenter technology and adding personnel necessary to operate as a public company with rapidly growing retail pharmacy operations in the United States. In addition, operating as a publicly traded company involves the hiring of additional financial and other personnel, upgrading our financial information systems and incurring costs associated with operating as a public company. We expect that our operating losses will decrease and turn positive as we execute our growth strategies within our operating segments. If our management
26

accelerates deployment into new states, operating losses could increase in the near-term, as we grow and scale our operations; we expect operating performance to turn positive once each state reaches sufficient scale in sales volume.
As of September 30, 2022, we had cash and cash equivalents of $27.2 million. We will continue to require additional capital to continue our technology development and commercialization activities and build out our pharmacy operations to serve our growing customer base. Accordingly, in November 2020, April 2022, and July 2022, we completed the sale of additional equity through private placement fundings, where we raised $83.9 million, $40.0 million, and $10.0 million in gross proceeds, respectively. Additionally, in June 2021 we entered into a term loan and borrowed $10.0 million. We expect to raise additional capital to continue funding operations. The amount and timing of future funding requirements will depend on many factors, including the pace and results of our growth strategy and capital market conditions. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop product candidates.
We have two reportable segments: Retail Pharmacy Services and Pharmacy Technology. These reportable segments are generally defined by how we execute our go-to-market strategy to sell products and services.
Overview of Retail Pharmacy Services Segment
The Retail Pharmacy Services operating segment operates as SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing our automated pharmacy technology, primarily servicing Medicare patients in the United States. In operating SpotRx, we employ the pharmacy team, purchase the medications, and deploy our proprietary technology, the MedCenter, directly into the Medicare-focused clinics. This is an end-to-end turnkey solution.
Overview of Pharmacy Technology Segment
MedAvail Technologies develops and commercializes the MedCenter for direct sale or subscription to third-party customers, including some of the world’s largest healthcare providers and systems, as well as large retail chains that provide full retail-pharmacy services using our technology.
Results of Operations for the Three Months Ended September 30, 2022
Revenue – Retail Pharmacy and Hardware and Service
Retail pharmacy and hardware revenue
Retail pharmacy revenue from the Retail Pharmacy Services segment is derived from sales of prescription medications and over-the-counter products to patients. Medications are sold and delivered by various methods including dispensing product directly from the MedCenter, patient pick up at MedAvail’s SpotRx pharmacy locations and home delivery of medications to patient residences. Hardware sales from the pharmacy technology segment are derived from either the sales or subscription of the MedCenter to customers.
Service revenue
Service revenue from the Pharmacy Technology Segment is derived from installation and support services.
27

Revenue
Three Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Pharmacy and hardware revenue:(in thousands)
Retail pharmacy revenue$11,162 $5,445 $5,717 105 %
Hardware— 106 (106)(100)%
Subscription104 108 (4)(4)%
Total pharmacy and hardware revenue11,266 5,659 5,607 99 %
Service revenue:
Software94 51 43 84 %
Maintenance and support48 44 4 9 %
Installation— 11 (11)(100)%
Professional services and other53 27 26 96 %
Total service revenue195 133 62 47 %
Total revenue$11,461 $5,792 $5,669 98 %
During the three months ended September 30, 2022, retail pharmacy and hardware revenue increased by $5.6 million to $11.3 million compared to that of the same period in 2021. The $5.6 million increase was due to a $5.7 million increase from volume growth in prescription revenue at existing sites and additional sites launched primarily in Florida in Q4 2021 and continuing into 2022.
During the three months ended September 30, 2022, service revenue increased by $0.1 million to $0.2 million compared to that of the same period in 2021.
Cost of Products Sold and Services
Retail pharmacy and hardware cost of products sold
Cost of products sold consists primarily of prescription medications, other over-the-counter health products; and costs associated with MedCenters sold to third-party customers.
Service costs
Service costs consists primarily of costs incurred to install and maintain MedCenters at third-party customer locations.
Costs of Products and Services
Three Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Retail pharmacy and hardware cost of products sold:(in thousands)
Prescription drugs$9,313 $4,969 $4,344 87 %
Shipping735 396 339 86 %
Hardware13 129 (116)(90)%
Depreciation52 45 7 16 %
Total retail pharmacy and hardware cost of products sold10,113 5,539 4,574 83 %
Service costs:
Professional services10 16 (6)(38)%
Maintenance and support services46 46 — — %
Installation services— 5 (5)(100)%
Total service costs56 67 (11)(16)%
Total cost of products sold and services$10,169 $5,606 $4,563 81 %
During the three months ended September 30, 2022, retail pharmacy and hardware cost of products sold increased $4.6 million to $10.1 million compared to the same period in 2021. The increase was primarily due to costs associated with volume growth in prescription sales at existing
28

sites and additional sites launched primarily in Florida in Q4 2021 and continuing into 2022. Shipping costs, related to our home delivery service via third-party courier, increased $0.3 million compared to the same period in 2021.
During the three months ended September 30, 2022, service costs were reasonably consistent with the same period in the prior year.
Pharmacy Operations
Pharmacy operations consist of costs incurred to operate retail pharmacies and our call center. Wages and salaries consist of compensation costs incurred for all pharmacy operations related employees and contractors including bonuses, health plans, severance, and contractor costs. Facility expenses consist of rent and utilities directly associated with our pharmacy operations.
Other pharmacy operations expenses consist of supply costs and other costs.
Depreciation of property, plant and equipment includes depreciation on MedCenters, IT equipment, leasehold improvements, general plant and equipment, software, office furniture and equipment and vehicles. Amortization of intangible assets consists of amortization of mobile applications and software.
Three Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Pharmacy operations expenses:(in thousands)
Wages and salaries$2,375 $2,794 $(419)(15)%
Rent, utilities, and other569 570 (1)(0)%
Depreciation of property, plant and equipment242 220 22 10 %
Amortization of intangible assets1,089 90 999 1110 %
Repairs and maintenance117 76 41 54 %
Total pharmacy operations expenses$4,392 $3,750 $642 17 %
During the three months ended September 30, 2022, pharmacy operations expenses increased by $0.6 million to $4.4 million compared to the same period in 2021. Amortization of intangible assets has increased due to deploying internally developed software in our pharmacy operations and decreasing the remaining useful life resulting in an increased amortization of $1.0 million. The increase was offset by the decrease in wages and salaries due to reduction in contractor costs.
General and Administrative
General and administrative expenses consist of personnel costs, facility expenses and expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and share-based compensation. Facility expenses consist of rent and other related costs specific to our corporate and technology activities. Corporate insurance, office supplies and technology expenses are also captured within general and administrative expenses. We incurred and expect to incur additional expenses as a result of being a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.
We have equity incentive plans whereby awards are granted to certain of our employees. The fair value of the stock options and restricted stock units granted by us to our employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. We measure the fair value of the stock options using the Black-Scholes option pricing model as of the grant date. Shares issued upon the exercise of stock options and vesting of restricted stock units are new shares. We estimate forfeitures based on historical experience and expense related to awards is adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are expensed.
29

Three Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
General and administrative expenses:(in thousands)
Wages and salaries$3,098 $2,695 $403 15 %
Professional services531 549 (18)(3)%
Share-based compensation565 367 198 54 %
Insurance503 462 41 9 %
Software licenses and support421 305 116 38 %
Rent, utilities, and other745 555 190 34 %
Office and IT supplies88 126 (38)(30)%
Travel and other employee expenses87 184 (97)(53)%
Depreciation of property, plant and equipment49 77 (28)(36)%
Total general and administrative expenses$6,087 $5,320 $767 14 %
During the three months ended September 30, 2022, general and administrative costs increased approximately by $0.8 million to $6.1 million compared to that of the same period in 2021. This increase was primarily due to hiring additional administrative staff, increased share-based compensation, as well as other investments necessary for our growth as a public company.
Selling and Marketing
Selling and marketing expenses consist of personnel costs, marketing and advertising costs, and marketing related expenses for outside professional services. Wages and salaries consist of compensation costs incurred for all selling and marketing employees including our in-clinic customer account managers, including bonuses, health plans, and severance.
Three Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Selling and marketing expenses:(in thousands)
Wages and salaries$1,960 $1,658 $302 18 %
Travel and other employee expenses86 126 (40)(32)%
Marketing74 110 (36)(33)%
Other selling and marketing expenses6 15 (9)(60)%
Total selling and marketing expenses$2,126 $1,909 $217 11 %
During the three months ended September 30, 2022, selling and marketing costs increased approximately by $0.2 million to $2.1 million compared to that of the same period in 2021. This increase was primarily due to personnel related costs associated with hiring additional Clinic Account Managers (CAMs), which directly support the staff and patients at the growing number of medical clinics where we are deployed.
Research and Development
Research and development expenses represent costs incurred to develop and innovate our MedCenter platform technology, including development work on hardware, software and supporting information technology infrastructure. Wages and salaries consist of compensation costs incurred for research and development employees and contractors including bonuses, health plans, severance, and contractor costs.
Three Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Research and development expenses:(in thousands)
Wages and salaries$166 $165 $1 1 %
Other expenses12 67 (55)(82)%
Total research and development expenses$178 $232 $(54)(23)%
During the three months ended September 30, 2022, research and development costs decreased by approximately $0.1 million.
30

Interest Income and Expense
Interest expense consists of accrued interest on outstanding debt and is payable monthly.
Three Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Interest income:(in thousands)
Interest income$— $7 $(7)(100)%
Total interest income$— $7 $(7)(100)%
Interest expense:
Interest expense$(315)$(260)$(55)21 %
Total interest expense$(315)$(260)$(55)21 %
During the three months ended September 30, 2022, interest expense increased compared to the same period in 2021 due to the Company entering into a term loan in June 2021. The interest rate on the term loan was 10.25% on September 30, 2022, compared to 7.25% on September 30, 2021. For more detail on outstanding debt and associated maturities, see Note 8 to the unaudited condensed consolidated financial statements presented elsewhere in this Quarterly Report on Form 10-Q.
Results of Operations for the Nine Months Ended September 30, 2022
Revenue – Retail Pharmacy and Hardware and Service
Retail pharmacy and hardware revenue
Retail pharmacy revenue from the Retail Pharmacy Services segment is derived from sales of prescription medications and over-the-counter products to patients. Medications are sold and delivered by various methods including dispensing product directly from the MedCenter, patient pick up at MedAvail’s SpotRx pharmacy locations or home delivery of medications to patient residences. Hardware sales from the pharmacy technology segment are derived from either the sales or subscription of the MedCenter to customers.
Service revenue
Service revenue from the Pharmacy Technology Segment is derived from installation and support services.
Revenue
Nine Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Pharmacy and hardware revenue:(in thousands)
Retail pharmacy revenue$30,652 $13,357 $17,295 129 %
Hardware236 470 (234)(50)%
Subscription322 338 (16)(5)%
Total pharmacy and hardware revenue31,210 14,165 17,045 120 %
Service revenue:
Software228 125 103 82 %
Maintenance and support127 115 12 10 %
Installation77 39 38 97 %
Professional services and other117 405 (288)(71)%
Total service revenue549 684 (135)(20)%
Total revenue$31,759 $14,849 $16,910 114 %
During the nine months ended September 30, 2022, retail pharmacy and hardware revenue increased by $17.0 million to $31.2 million compared to that of the same period in 2021. The $17.0 million increase was due to a $17.3 million increase from volume growth in prescription revenue at existing sites and additional sites launched primarily in Florida in Q4 2021 and continuing into 2022, offset by the decrease in hardware revenue from the same period in 2021.
31

During the nine months ended September 30, 2022, service revenue decreased by $0.1 million to $0.5 million compared to the same period in 2021.
Cost of Products Sold and Services
Retail pharmacy and hardware cost of products sold
Cost of products sold consists primarily of prescription medications, other over-the-counter health products; and costs associated with MedCenters sold to third-party customers.
Service costs
Service costs consist primarily of costs incurred to install and maintain MedCenters at third-party customer locations.
Costs of Products and Services
Nine Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Retail pharmacy and hardware cost of products sold:(in thousands)
Prescription drugs$26,402 $12,154 $14,248 117 %
Shipping2,059 976 1,083 111 %
Hardware245 482 (237)(49)%
Depreciation121 132 (11)(8)%
Total retail pharmacy and hardware cost of products sold28,827 13,744 15,083 110 %
Service costs:
Professional services33 301 (268)(89)%
Maintenance and support services139 105 34 32 %
Installation services49 20 29 145 %
Total service costs221 426 (205)(48)%
Total cost of products sold and services$29,048 $14,170 $14,878 105 %
During the nine months ended September 30, 2022, retail pharmacy and hardware cost of products sold increased by $15.1 million to $28.8 million compared to that of the same period in 2021. The increase was primarily due to costs associated with volume growth in prescription sales at existing sites and additional sites launched primarily in Florida in Q4 2021 and continuing into 2022. Shipping costs, related to our home delivery service via third-party courier, increased by $1.1 million compared to that of the same period in 2021.
Pharmacy Operations
Pharmacy operations consist of costs incurred to operate retail pharmacies and our call center. Wages and salaries consist of compensation costs incurred for all pharmacy operations related employees and contractors including bonuses, health plans, severance, and contractor costs. Facility expenses consist of rent and utilities directly associated with our pharmacy operations.
Other pharmacy operations expenses consist of supply cost and other costs.
Depreciation of property, plant and equipment includes depreciation on MedCenters, IT equipment, leasehold improvements, general plant and equipment, software, office furniture and equipment and vehicles. Amortization of intangible assets consists of amortization of mobile applications and software.
32

Nine Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Pharmacy operations expenses:(in thousands)
Wages and salaries$7,970 $7,330 $640 9 %
Rent, utilities, and other1,602 1,102 500 45 %
Depreciation of property, plant and equipment694 641 53 8 %
Amortization of intangible assets1,362 187 1,175 628 %
Repairs and maintenance342 168 174 104 %
Total pharmacy operations expenses$11,970 $9,428 $2,542 27 %
During the nine months ended September 30, 2022, pharmacy operations expenses increased by $2.5 million to $12.0 million compared to that of the same period in 2021. This increase was primarily due to adding our Orlando central pharmacy location in Q4 2021 and continued growth of our other pharmacies. Additionally, volume growth continued to ramp up at existing pharmacy locations, thus increasing pharmacy personnel and supplies, resulting in increased wages, salaries, and operating costs. Amortization of intangible assets has increased as a result of deploying internally developed software in our pharmacy operations and decreasing the remaining useful life resulting in an increased amortization of $1.0 million
General and Administrative
General and administrative expenses consist of personnel costs, facility expenses and expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and share-based compensation. Facility expenses consist of rent and other related costs specific to our corporate and technology activities. Corporate insurance, office supplies and technology expenses are also captured within general and administrative expenses. We incurred and expect to incur additional expenses as a result of being a public company, including expenses related to compliance with the rules and regulations of the SEC, Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.
We have an equity incentive plan whereby awards are granted to certain of our employees. The fair value of the stock options and restricted stock units granted by us to our employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. We measure the fair value of the stock options using the Black-Scholes option pricing model as of the grant date. Shares issued upon the exercise of stock options and vesting of restricted stock units are new shares. We estimate forfeitures based on historical experience and expense related to awards are adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are expensed.
Nine Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
General and administrative expenses:(in thousands)
Wages and salaries$9,699 $8,044 $1,655 21 %
Professional services2,087 2,714 (627)(23)%
Share-based compensation1,741 948 793 84 %
Insurance1,509 1,357 152 11 %
Software licenses and support1,132 785 347 44 %
Rent, utilities, and other1,944 1,895 49 3 %
Office and IT supplies286 270 16 6 %
Travel and other employee expenses212 566 (354)(63)%
Depreciation of property, plant and equipment119 154 (35)(23)%
Total general and administrative expenses$18,729 $16,733 $1,996 12 %
During the nine months ended September 30, 2022, general and administrative costs increased approximately by $2.0 million to $18.7 million compared to that of the same period in 2021. This increase was primarily due to hiring additional administrative staff, increased share-based compensation, as well as other investments necessary for our growth as a public company. Professional services decreased approximately by $0.6 million to $2.1 million compared to that of the same period in 2021. This decrease was primarily due to the reduction of fees from data warehousing, legal and audit costs.
33

Selling and Marketing
Selling and marketing expenses consist of personnel costs, marketing and advertising costs, and marketing related expenses for outside professional services. Wages and salaries consist of compensation costs incurred for all selling and marketing employees including our in-clinic customer account managers, and contractors including bonuses, health plans, and severance.
Nine Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Selling and marketing expenses:(in thousands)
Wages and salaries$6,167 $4,411 $1,756 40 %
Travel and other employee expenses286 242 44 18 %
Marketing260 378 (118)(31)%
Other selling and marketing expenses25 25 0 0 %
Total selling and marketing expenses$6,738 $5,056 $1,682 33 %
During the nine months ended September 30, 2022, selling and marketing costs increased approximately by $1.7 million to $6.7 million compared to that of the same period in 2021. This increase was primarily due to personnel related costs associated with hiring additional Clinic Account Managers (CAMs) which directly support the staff and patients at the growing number of medical clinics where we are deployed.
Research and Development
Research and development expenses represent costs incurred to develop and innovate our MedCenter platform technology, including development work on hardware, software and supporting information technology infrastructure. Wages and salaries consist of compensation costs incurred for research and development employees and contractors including bonuses, health plans, severance, and contractor costs.
Nine Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Research and development expenses:(in thousands)
Wages and salaries$534 $498 $36 7 %
Other expenses418 103 315 306 %
Total research and development expenses$952 $601 $351 58 %
During the nine months ended September 30, 2022, research and development costs increased by approximately $0.4 million. This increase was primarily due to ongoing product improvement activities, including efforts to integrate our MedPlatform® Enterprises Software with the EPIC pharmacy management system for material and subcontractor costs reflected in other expenses.
Interest Income and Expense
Interest expense consists of accrued interest on outstanding debt and is payable monthly.
Nine Months Ended September 30,2022 vs. 2021
20222021Amount Change% Change
Interest income:(in thousands)
Interest income$1 $74 $(73)(99)%
Total interest income$1 $74 $(73)(99)%
Interest expense:
Interest expense$(845)$(328)$(517)158 %
Total interest expense$(845)$(328)$(517)158 %
During the nine months ended September 30, 2022, interest expense increased compared to the same period in 2021 due to the Company entering into a term loan in June 2021. The interest rate on the term loan was 10.25% on September 30, 2022, compared to 7.25% on September 30, 2021. For more detail on outstanding debt and associated maturities, see Note 8 to the unaudited condensed consolidated financial statements presented elsewhere in this Quarterly Report on Form 10-Q.
34


Liquidity and Capital Resources
Sources of Liquidity
Since inception through September 30, 2022, our operations have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. As of September 30, 2022, we had $27.2 million in cash and cash equivalents and an accumulated deficit of $228.6 million. We added to our liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank or the Loan Agreement, pursuant to which we borrowed $10.0 million in aggregate initial term loans. In April 2022, we completed a private placement, pursuant to which we received $40.0 million in gross proceeds before deducting placement agent commissions and other offering expenses. An additional $10.0 million in gross proceeds closed on July 1, 2022.
In connection with the private placement, we issued callable warrants in April 2022 and July 2022. The warrant call option is exercisable by us beginning on each of the 12-month and 24-month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of our shares. If the warrants are exercised in full immediately after issuance by the Investors, we would receive additional gross proceeds of up to $29.4 million. If we exercise our call option immediately after issuance, then we could raise approximately $19.6 million in gross proceeds.
Management is also exploring additional sources of financing, the success of which is dependent on market conditions. Management has concluded that the aforementioned conditions, including the ongoing uncertainty related to the negative impacts of the COVID-19 pandemic and the economic uncertainties related to the conflict in Ukraine resulting from the military actions of Russia, including on the global economy, interest rate fluctuations, inflationary pressures and our supply chain, raise substantial doubt about our ability to continue as a going concern within 12 months from the date of issuance of the financial statements. Our plans to address this uncertainty include raising additional funding, as necessary, through public or private equity or debt financings.
However, we may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if we issue equity securities to raise additional funds, our existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of our existing stockholders. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Our management actively evaluates matters of liquidity and growth capital needs, including evaluating debt and equity as sources of growth capital with a focus on lower overall weighted average cost of capital and favorable financing terms. Our primary uses of liquidity are operating activities, capital expenditures, and lease payments.
Cash Flows
The following table summarizes our cash flows:
Nine Months Ended September 30,
2022 vs. 2021
(In thousands)20222021Amount Change% Change
Cash used in operating activities$(37,283)$(28,174)$(9,109)32 %
Cash used in investing activities(1,897)(2,269)372 (16)%
Cash provided by financing activities46,963 8,722 38,241 438 %
Net increase (decrease) in cash and cash equivalents, and restricted cash$7,783 $(21,721)$29,504 (136)%
Operating Activities
During the nine months ended September 30, 2022, cash used in operating activities increased by $9.1 million to $37.3 million compared to that of the same period in 2021. The increase was primarily due to an increase in inventory, accounts receivable, operating expenses from wages and salaries, and costs attributable to the launch and growth of our retail pharmacy operations in Arizona, California, Michigan, and Florida, and operating as a public company.
Investing Activities
During the nine months ended September 30, 2022, cash used in investing activities decreased by $0.4 million to $1.9 million compared to that of the same period in 2021. The decrease was primarily due to a decrease in investment in intangible assets associated with investments in Retail Pharmacy Services Segment.
35

Financing Activities
During the nine months ended September 30, 2022, cash provided by financing activities increased by $38.2 million to $47.0 million compared to that of the same period in 2021. The increase was primarily due to issuance of common shares and warrants through a private placement in April 2022 and July 2022, with no similar activity during the nine months ended September 30, 2021, offset by $10.0 million from debt proceeds during the nine months ended September 30, 2021, with no similar activity in the current period.

Critical Accounting Estimates
There were no significant changes in our critical accounting estimates in the nine months ended September 30, 2022, from those previously disclosed in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 29, 2022.
Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements, see Part II, Item 8, Note 5 of our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 29, 2022, and Note 4: "Recent Accounting Pronouncements" in the notes to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report Form 10-Q.

36

Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective.
Changes in Internal Control Over Financial Reporting
There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
37

PART II
Item 1. Legal Proceedings
The information set forth under the heading “Legal” in Note 10, Commitments and Contingencies, in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.

Item 1A. Risk Factors
Except as set forth below, there have been no material changes from the risk factors disclosed in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021, or the “2021 Annual Report", filed with the Securities and Exchange Commission on March 29, 2022. The risk factors described in our 2021 Annual Report, as well as other information set forth in this Quarterly Report on Form 10-Q, could materially adversely affect our business, financial condition, results of operations and prospects, and should be carefully considered. The risks and uncertainties that we face, however, are not limited to those described in the 2021 Annual Report. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business and the trading price of our securities, particularly in light of the fast-changing nature of the COVID-19 pandemic, containment measures and the related impacts to economic and operating conditions.
Our share price does not meet the minimum bid price for continued listing on Nasdaq. Our ability to continue operations or to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we do not regain compliance with the minimum bid price requirement and we are delisted from Nasdaq.

We received a deficiency letter from Nasdaq notifying us that for the last 30 consecutive business days the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days starting on October 31, 2022 or until May 1, 2023, to regain compliance with the Bid Price Rule. If, at any time before May 1, 2023, the bid price for our common stock closes at $1.00 or more for a minimum of 10 consecutive business days, we will regain compliance with the Bid Price Rule, unless the Nasdaq staff exercises its discretion to extend this 10-day period pursuant to Nasdaq listing rules. We have not regained compliance with Nasdaq Listing Rules as of the filing date of this Quarterly Report on Form 10-Q.

If we do not regain compliance with Nasdaq Listing Rule 5550(a)(2) by May 1, 2023, we may be eligible for additional time to comply. To qualify, we will be required to meet certain continued listing requirements for market value of publicly held shares and all other initial listing standards for Nasdaq. If we meet these requirements, Nasdaq may grant us an additional 180 calendar days to regain compliance with the Bid Price Rule, and we may provide written notice to Nasdaq of our intention to cure the deficiency during the additional compliance period. One method to regain compliance in such circumstances would be to implement a reverse stock split, but there is no guarantee that a reverse stock split would be approved by the stockholders or that a reverse stock split would allow us to regain compliance with the Bid Price Rule, and such an action could result in an adverse effect on or negatively impact the price of our common stock.

If we do not regain compliance with the Bid Price Rule and are not eligible for or are not granted an additional compliance period, our common stock may be delisted. There can be no assurance that, if we receive a delisting notice and appeal the delisting determination by the staff, such appeal would be successful. There can be no assurance that we will maintain compliance with the requirements for listing our common stock on Nasdaq.

Delisting could adversely affect our ability to raise additional capital through the public or private sale of equity securities, which would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our common stock.

We and our stockholders could be materially adversely impacted if our common stock is delisted from Nasdaq. In particular:

•we may lose the confidence of our current or prospective third-party providers and collaboration partners, which could jeopardize our ability to enter into supply, manufacturing, licensing, and collaboration agreements and continue our business as currently conducted;
•we could be in a material breach under agreements we have with third parties, such as the Loan and Security Agreement between us and Silicon Valley Bank;
•the price of our common stock will likely decrease;
•stockholders may be unable to sell or purchase our common stock when they wish to do so;
•the potential loss of confidence by employees;
•we may lose the interest of institutional investors in our common stock;
•we may have fewer business development opportunities;
•we may lose media and analyst coverage;
•our common stock could be considered a “penny stock,” which would likely limit the level of trading activity in the secondary market for our common stock; and
38

•we would likely lose the active trading market for our common stock, as it may only be traded on one of the over-the-counter markets, if at all.

As of the date of this Quarterly Report on Form 10-Q, except for the risk factor described above with respect to the deficiency in connection with the Bid Price Rule, there have been no material changes to the risk factors disclosed in the 2021 Annual Report filed with the Securities and Exchange Commission on March 29, 2022. We may disclose additional changes to such factors or disclose additional factors from time to time in our future filings with the Securities and Exchange Commission.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On July 1, 2022, the Company sold and issued 9,411,765 Shares and Warrants to purchase 4,705,881 Warrant Shares in a private placement, which was previously disclosed by the Company on its Current Report on Form 8-K filed July 1, 2022.

Item 3. Defaults Upon Senior Securities
None.

Item 4. Mine Safety Disclosures
None.

Item 5. Other Information
None.

39

Item 6. Exhibits
Incorporated by Reference
Exhibit NumberDescriptionFormExhibitFiling Date
3.18-K3.1June 16, 2022
3.28-K3.2November 18, 2020
4.18-K4.1November 18, 2020
4.2S-4/A4.9October 9, 2020
4.38-K4.3November 18, 2020
4.48-K10.1April 4, 2022
4.58-K10.2April 4, 2022
4.68-K10.3April 4, 2022
4.7S-31.2August 12, 2022
10.1#8-K10.1April 8, 2022
16.18-K16.1July 11, 2022
31.1*
31.2*
32.1**
101*Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q
104*Inline XBRL for the cover page of this Quarterly on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set
§ Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) and Item 601(b)(10).
# Indicates a management contract or compensatory plan.
* Filed herewith.
** Furnished herewith.
40

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.


MEDAVAIL HOLDINGS, INC.
Date: November 10, 2022By:/s/ Mark Doerr
 Mark Doerr
 President, Chief Executive Officer, and Principal Executive Officer
By:/s/ Ramona Seabaugh
Ramona Seabaugh
Chief Financial Officer and Principal Financial Officer


41
MYOS RENS Technology (NASDAQ:MYOS)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse MYOS RENS Technology
MYOS RENS Technology (NASDAQ:MYOS)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse MYOS RENS Technology